Georg Aue

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Mohammed Farooqui, Janet Valdez, Sabrina Martyr et al. · The Lancet Oncology · 2014 · 366 citations · Full text

Medicine, Immunology, Oncology +11

Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib

Clare Sun, Xin Tian, Yuh Shan Lee et al. · Blood · 2015 · 221 citations · Full text

Life Sciences, Hematology, Immunology +14

Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

Inhye E. Ahn, Mohammed Farooqui, Xin Tian et al. · Blood · 2018 · 204 citations · Full text

Medicine, Pharmacology, Pharmacodynamics +4

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Sarah E. M. Herman, Carsten Utoft Niemann, Mahfooz Farooqui et al. · Leukemia · 2014 · 190 citations · Full text

Medicine, Hematology, Oncology +15

Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood

Thomas M. Herndon, S-S Chen, Nakhle S. Saba et al. · Leukemia · 2017 · 130 citations

Medicine, Cell Biology, Oncology +15